HGEN News and Press, Humanigen Inc. From 03/31/21

Humanigen (HGEN) has priced its public offering of 5M common shares at 18.50/share, resulting in gross proceeds of ~$92.5M.Underwriters' over-allotment is an additional 750K shares. Net proceeds will be used for manufacturing and commercial preparation of COVID-19 candidate lenzilumab in the ...

Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab™, today announced that it has priced its...

Top Biotech Stocks To Watch This Week Some say that we are living in the golden age of biotechnology. Even if you disagree, there’s no denying that investors who have bet on biotech stocks have seen astronomical gains in the last year. These stocks have been highly sought...

Humanigen (HGEN) has started an underwritten public offering of 5M shares of common stock.Underwriters have a 30-day option to purchase up to an additional 750K shares.Jefferies, Credit Suisse, and Cantor are joint book-runners.Humanigen says it plans to use the proceeds from the offering for...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab TM , today announced that it has commenced...

Avid Biosciences (CDMO) will benefit from positive top-line phase 3 results released this morning for Humanigen's (HGEN) COVID-19 therapy candidate lenlizumab through a contract, according to RBC analyst Sean Dodge.Avid's Current Good Manufacturing Process (cGMP) contract with Humanigen,...

While shares of Humanigen (HGEN) are up 54.1% to $21.56 in afternoon trading, J.P. Morgan analyst Eric Joseph is maintaining his neutral rating and $21 price target.This morning, the company released positive phase 3 data on COVID-19 therapy candidate lenzilumab."Despite suppor...

Shares of clinical-stage biopharmaceutical company Humanigen (NASDAQ: HGEN) are soaring through the roof on Monday after the company reported positive top-line results from a clinical trial for one of its pipeline candidates, lenzilumab. As of 1:20 p.m. EDT, the company's stock was ...

Gainers: Humanigen (HGEN) +81%.Universe Pharmaceuticals (UPC) +70%.SeaChange International (SEAC) +60%.Elite Education Group International (EEIQ) +34%.Cyanotech (CYAN) +34%.Fly Leasing (FLY) +27%.Trinity Biotech (TRIB) +25%.Virpax Pharmaceuticals (VRPX) +21%.Hall of Fame Resort & Ent...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cruise stocks are taking on water Monday after the Centers for Disease Control and Prevention (CDC) dashed hopes for sailing to resume sooner than expected. Source: Shutterstock.com Cruise companies were pushing for...